+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Computational Biology - Global Market Trajectory & Analytics

  • ID: 5139849
  • Report
  • April 2021
  • Region: Global
  • 176 Pages
  • Global Industry Analysts, Inc
Global Computational Biology Market to Reach $9.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Computational Biology estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at a CAGR of 19.2% over the analysis period 2020-2027. Cellular & Biological Simulation, one of the segments analyzed in the report, is projected to record a 18.1% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drug Discovery & Disease Modelling segment is readjusted to a revised 18.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $798.4 Million, While China is Forecast to Grow at 18.5% CAGR

The Computational Biology market in the U.S. is estimated at US$798.4 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 18.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.6% and 16.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14% CAGR.

Preclinical Drug Development Segment to Record 23.6% CAGR

In the global Preclinical Drug Development segment, USA, Canada, Japan, China and Europe will drive the 23.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$149.5 Million in the year 2020 will reach a projected size of US$650.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2027.

Select Competitors (Total 42 Featured):
  • Certara LP
  • Chemical Computing Group ULC
  • Compugen Ltd.
  • Dassault Systemes
  • Genedata AG
  • Insilico Biotechnology AG
  • Leadscope, Inc.
  • Nimbus Therapeutics
  • Rosa & Co. LLC
  • Schrodinger LLC
  • Simulations Plus, Inc.
  • Strand Life Sciences Pvt., Ltd.
Frequently Asked Questions about the Global Market for Computational Biology

What is the estimated value of the Global Market for Computational Biology?

The Global Market for Computational Biology was estimated to be valued at $2.7 Billion in 2020.

What is the growth rate of the Global Market for Computational Biology?

The growth rate of the Global Market for Computational Biology is 19.1%, with an estimated value of $9.2 Billion by 2027.

What is the forecasted size of the Global Market for Computational Biology?

The Global Market for Computational Biology is estimated to be worth $9.2 Billion by 2027.
Note: Product cover images may vary from those shown

I. METHODOLOGY
II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Computational Biology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Computational Biology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Cellular & Biological Simulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Cellular & Biological Simulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Drug Discovery & Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Drug Discovery & Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Preclinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Preclinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Human Body Simulation Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Human Body Simulation Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for In-House Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for In-House Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Contract Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Contract Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 21: World Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 22: World 7-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS
  • Table 23: USA Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: USA 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 25: USA Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: USA 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 27: USA Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: USA 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 29: Canada Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Canada 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 33: Canada Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 34: Canada 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 35: Japan Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 36: Japan 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 37: Japan Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 39: Japan Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: Japan 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 41: China Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: China 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 43: China Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: China 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 45: China Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 46: China 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 47: Europe Current & Future Analysis for Computational Biology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 48: Europe 7-Year Perspective for Computational Biology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 49: Europe Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Europe 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 51: Europe Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Europe 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 53: Europe Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Europe 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 55: France Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: France 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 57: France Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 58: France 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 59: France Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: France 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 61: Germany Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Germany 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 63: Germany Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Germany 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 65: Germany Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Germany 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 67: Italy Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Italy 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 69: Italy Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 70: Italy 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 71: Italy Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 72: Italy 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 73: UK Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: UK 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 75: UK Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 76: UK 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 77: UK Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 78: UK 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 79: Rest of Europe Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: Rest of Europe 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 81: Rest of Europe Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 82: Rest of Europe 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 83: Rest of Europe Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 84: Rest of Europe 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 85: Asia-Pacific Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: Asia-Pacific 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 87: Asia-Pacific Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 88: Asia-Pacific 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 89: Asia-Pacific Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 90: Asia-Pacific 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027
  • Table 91: Rest of World Current & Future Analysis for Computational Biology by Application Area - Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of World 7-Year Perspective for Computational Biology by Application Area - Percentage Breakdown of Value Sales for Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software for the Years 2020 & 2027
  • Table 93: Rest of World Current & Future Analysis for Computational Biology by Service - In-House Services and Contract Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 94: Rest of World 7-Year Perspective for Computational Biology by Service - Percentage Breakdown of Value Sales for In-House Services and Contract Services for the Years 2020 & 2027
  • Table 95: Rest of World Current & Future Analysis for Computational Biology by End-Use - Academics, Industry and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 96: Rest of World 7-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academics, Industry and Commercial for the Years 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown